SG11201504986QA - Short-acting factor vii polypeptides - Google Patents

Short-acting factor vii polypeptides

Info

Publication number
SG11201504986QA
SG11201504986QA SG11201504986QA SG11201504986QA SG11201504986QA SG 11201504986Q A SG11201504986Q A SG 11201504986QA SG 11201504986Q A SG11201504986Q A SG 11201504986QA SG 11201504986Q A SG11201504986Q A SG 11201504986QA SG 11201504986Q A SG11201504986Q A SG 11201504986QA
Authority
SG
Singapore
Prior art keywords
short
factor vii
acting factor
vii polypeptides
polypeptides
Prior art date
Application number
SG11201504986QA
Inventor
Maxine Bauzon
Terry Hermiston
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51022016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201504986Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of SG11201504986QA publication Critical patent/SG11201504986QA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6437Coagulation factor VIIa (3.4.21.21)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4846Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21021Coagulation factor VIIa (3.4.21.21)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
SG11201504986QA 2012-12-24 2013-12-23 Short-acting factor vii polypeptides SG11201504986QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261745674P 2012-12-24 2012-12-24
US201361787026P 2013-03-15 2013-03-15
PCT/US2013/077405 WO2014105784A1 (en) 2012-12-24 2013-12-23 Short-acting factor vii polypeptides

Publications (1)

Publication Number Publication Date
SG11201504986QA true SG11201504986QA (en) 2015-07-30

Family

ID=51022016

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201710593UA SG10201710593UA (en) 2012-12-24 2013-12-23 Short-acting factor vii polypeptides
SG11201504986QA SG11201504986QA (en) 2012-12-24 2013-12-23 Short-acting factor vii polypeptides

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201710593UA SG10201710593UA (en) 2012-12-24 2013-12-23 Short-acting factor vii polypeptides

Country Status (21)

Country Link
US (5) US20150344863A1 (en)
EP (3) EP2938351B8 (en)
JP (3) JP6566869B2 (en)
KR (2) KR102111934B1 (en)
CN (2) CN105025913A (en)
AU (2) AU2013370522B2 (en)
BR (1) BR112015015182B1 (en)
CA (2) CA2896057C (en)
DK (3) DK3572090T3 (en)
ES (3) ES2747726T3 (en)
HK (1) HK1216855A1 (en)
IL (2) IL239345B (en)
MX (2) MX2015007712A (en)
NZ (1) NZ708873A (en)
PE (2) PE20151206A1 (en)
PL (3) PL3165232T3 (en)
SA (1) SA517380867B1 (en)
SG (2) SG10201710593UA (en)
TW (3) TWI708783B (en)
WO (1) WO2014105784A1 (en)
ZA (1) ZA201505315B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3572090T3 (en) 2012-12-24 2023-01-09 Coagulant Therapeutics Corp SHORT-ACTING FACTOR-VII POLYPEPTIDES
TW201629215A (en) * 2014-09-30 2016-08-16 拜耳保健有限責任公司 Compositions and methods for treatment with hemopexin
KR101755838B1 (en) 2015-09-09 2017-07-07 현대자동차주식회사 Engine preheating apparatus and method
CA3036527A1 (en) * 2016-09-13 2018-03-22 Bayer Healthcare Llc Factor viia glycoforms
KR102120921B1 (en) * 2017-02-10 2020-06-10 주식회사 일리아스바이오로직스 Process for preparing exosome loading β-glucocerebrosidase, and pharmaceutical composition for use in preventing and treating Gaucher Disease containing the same as an active ingredient
CN114728044A (en) 2019-08-15 2022-07-08 介控生化科技公司 Modified factor VII polypeptides for subcutaneous administration and on-demand treatment

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3008252A (en) 1959-02-02 1961-11-14 Beatrice V Robinson Puffed sleeve ironer
US5180583A (en) 1985-11-26 1993-01-19 Hedner Ulla K E Method for the treatment of bleeding disorders
FR2632524B1 (en) * 1988-06-09 1992-03-13 Fondation Nale Transfusion San PROCESS FOR THE PREPARATION OF A CONCENTRATED FRACTION IN FACTOR VIIA AND ITS APPLICATION AS A MEDICAMENT
RU2278123C2 (en) 2000-02-11 2006-06-20 Максиджен Холдингз Лтд. Molecules similar to factor vii or viia
EP1299126B1 (en) 2000-05-23 2004-10-27 Neurologix, Inc. Glutamic acid decarboxylase (gad) delivery system for treating neurodegenerative diseases
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US20050221335A1 (en) 2001-12-14 2005-10-06 Anthony Kavanagh Reporter gene
NZ536340A (en) * 2002-04-30 2006-09-29 Maxygen Holdings Ltd Factor VII or VIIa polypeptide variants with N-glycosylation
US8512710B2 (en) 2002-11-22 2013-08-20 Ansun Biopharma, Inc. Class of therapeutic protein based molecules
US7807174B2 (en) 2002-11-22 2010-10-05 Nexbio, Inc. Class of therapeutic protein based molecules
EP1608745B1 (en) * 2003-03-20 2009-05-13 Bayer HealthCare LLC FVII OR FVIIa VARIANTS
BRPI0411650A (en) * 2003-06-19 2006-08-08 Maxygen Holdings Ltd polypeptide variant of factor vii (fvii) or factor viia (fviia), nucleotide sequence, expression vector, host cell, composition, use of a variant, and method for treating a mammal having a disease or disorder in which clot formation is desirable
US20060198819A1 (en) * 2003-08-08 2006-09-07 Novo Nordisk Healthcare A/G Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
CN101870729A (en) * 2003-09-09 2010-10-27 诺和诺德医疗保健公司 Coagulation factor vii polypeptides
US8609370B2 (en) 2004-02-13 2013-12-17 Glycotope Gmbh Highly active glycoproteins-process conditions and an efficient method for their production
CA2564039A1 (en) 2004-05-10 2005-11-17 Basf Plant Science Gmbh Methods for assembling multiple expression constructs
EP1761630A2 (en) * 2004-06-21 2007-03-14 Novo Nordisk Health Care AG Glycosylation-disrupted factor vii variants
CA2598528A1 (en) 2005-03-11 2006-09-14 Fresenius Kabi Deutschland Gmbh Production of bioactive glycoproteins from inactive starting material
EP1893230A2 (en) * 2005-04-26 2008-03-05 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
EP1907540B1 (en) * 2005-07-22 2012-12-19 Bayer HealthCare LLC In-solution activation of factor vii
EP1937719A4 (en) 2005-08-19 2010-11-24 Novo Nordisk As Glycopegylated factor vii and factor viia
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
KR20080074166A (en) * 2005-11-08 2008-08-12 아스테라스 세이야쿠 가부시키가이샤 Compositions and methods for treating thrombocytopenia
EA015942B1 (en) * 2006-05-05 2011-12-30 Милленниум Фамэсьютикэлс, Инк. Substituted imidazoles, composition based thereon, a method for preventing or treating undesired thrombosis using thereof and method for inhibiting the coagulation of a blood sample
FR2901707B1 (en) 2006-05-31 2017-09-29 Lab Francais Du Fractionnement RECOMBINANT OR TRANSGENIC FACTOR VII COMPOSITION, EACH FACTOR VII MOLECULE HAVING TWO N-GLYCOSYLATION SITES WITH DEFINED GLYCANNIC PATTERNS
US7532621B2 (en) 2006-08-30 2009-05-12 Cornell Research Foundation, Inc. Lateral error correction for time-critical multicast
US20100026939A1 (en) 2006-12-20 2010-02-04 Sumitomo Chemical Company, Limited Polarizer and liquid crystal display device
KR101667981B1 (en) 2006-12-28 2016-10-20 얀센 바이오테크 인코포레이티드 Methods and vectors for generating asialylated immunoglobulins
NZ578882A (en) * 2007-02-20 2012-01-12 Dsm Ip Assets Bv Sialidase from the fungus Penicilium chrysogenum
JP6050927B2 (en) 2007-04-26 2016-12-21 シーエヌジェイ ホールディングス,インコーポレイテッド Recombinant vitamin K-dependent protein having high sialic acid content and method for preparing the same
US8273723B2 (en) 2007-10-12 2012-09-25 Sigma-Aldrich Co. Llc Compositions and methods for improved glycoprotein sialylation
TWI538916B (en) * 2008-04-11 2016-06-21 介控生化科技公司 Factor vii polypeptides that are modified and uses thereof
EP2987498B1 (en) * 2008-05-02 2017-07-05 Laboratoire Français du Fractionnement et des Biotechnologies Treatment of bleeding with low half-life fibrinogen
JP2010022253A (en) * 2008-07-17 2010-02-04 Kaneka Corp Method for making asialo sugar chain compound
CN102307562A (en) 2008-12-05 2012-01-04 加利福尼亚大学董事会 Methods and compositions for treating P.acnes
US8400974B2 (en) * 2009-07-30 2013-03-19 Apple Inc. Methods and apparatus for providing dynamic information in a wireless information channel
WO2011109600A1 (en) 2010-03-05 2011-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation pattern of a polypeptide
WO2013017555A1 (en) * 2011-08-01 2013-02-07 Lfb-Biotechnologies Factor vii compositions with specific glycosylation for controlled half-life
DK3572090T3 (en) 2012-12-24 2023-01-09 Coagulant Therapeutics Corp SHORT-ACTING FACTOR-VII POLYPEPTIDES

Also Published As

Publication number Publication date
AU2013370522A1 (en) 2015-07-09
EP2938351A4 (en) 2016-08-24
EP3165232B1 (en) 2019-07-10
EP2938351B8 (en) 2019-07-31
US20140363419A1 (en) 2014-12-11
KR102111934B1 (en) 2020-05-18
KR20190072686A (en) 2019-06-25
IL273559B (en) 2022-04-01
EP3165232A1 (en) 2017-05-10
JP2017071608A (en) 2017-04-13
ES2936485T3 (en) 2023-03-17
TWI681968B (en) 2020-01-11
WO2014105784A1 (en) 2014-07-03
CN105025913A (en) 2015-11-04
CN107099522A (en) 2017-08-29
US20150344863A1 (en) 2015-12-03
EP3572090A1 (en) 2019-11-27
BR112015015182B1 (en) 2023-12-26
US20210002624A1 (en) 2021-01-07
MX2015007712A (en) 2015-09-07
PE20211303A1 (en) 2021-07-20
ES2746116T3 (en) 2020-03-04
TW201431876A (en) 2014-08-16
US11530401B2 (en) 2022-12-20
EP3572090B1 (en) 2022-12-14
JP2016507506A (en) 2016-03-10
JP6363677B2 (en) 2018-07-25
HK1216855A1 (en) 2016-12-09
NZ708873A (en) 2019-11-29
BR112015015182A2 (en) 2019-07-30
KR102047235B1 (en) 2019-11-22
US20230295596A1 (en) 2023-09-21
AU2019202663B2 (en) 2020-09-10
TW202026309A (en) 2020-07-16
JP6566869B2 (en) 2019-08-28
KR20150127573A (en) 2015-11-17
US20160376578A1 (en) 2016-12-29
US10273466B2 (en) 2019-04-30
PL2938351T3 (en) 2020-03-31
TWI743542B (en) 2021-10-21
IL239345A0 (en) 2015-07-30
PL3165232T3 (en) 2019-12-31
ZA201505315B (en) 2022-11-30
TW201920254A (en) 2019-06-01
EP2938351B1 (en) 2019-06-26
DK3165232T3 (en) 2019-09-16
MX2021002985A (en) 2021-05-14
IL239345B (en) 2020-04-30
DK3572090T3 (en) 2023-01-09
ES2747726T3 (en) 2020-03-11
IL273559A (en) 2020-05-31
TWI708783B (en) 2020-11-01
AU2019202663A1 (en) 2019-05-09
SA517380867B1 (en) 2020-06-10
PL3572090T3 (en) 2023-04-11
AU2013370522B2 (en) 2019-01-17
SG10201710593UA (en) 2018-02-27
CA3185756A1 (en) 2014-07-03
CA2896057A1 (en) 2014-07-03
DK2938351T3 (en) 2019-09-23
AU2013370522A2 (en) 2016-10-06
PE20151206A1 (en) 2015-09-04
JP2019213540A (en) 2019-12-19
US10717970B2 (en) 2020-07-21
NZ749488A (en) 2021-09-24
EP2938351A1 (en) 2015-11-04
CA2896057C (en) 2023-03-14

Similar Documents

Publication Publication Date Title
IL291571A (en) Cx3cr1-binding polypeptides
IL254716B (en) Zinc-lysine complex
HK1211258A1 (en) Chromatographic materials
HK1211340A1 (en) Portable spectrometer
ZA201309174B (en) Polypeptides
ZA201503358B (en) Structure
GB201220474D0 (en) Polypeptides
GB201213567D0 (en) Biomarkers
IL273559B (en) Short-acting factor vii polypeptides
PL2875059T3 (en) Intermediate polyisocyanurate comprising materials
GB201319035D0 (en) Spolier structure
EP2828282A4 (en) Biomarkers
GB201210565D0 (en) Biomarkers
HUP1300640A2 (en) Belt-mounting structure
EP2871919A4 (en) Structure
EP2912953A4 (en) Macaroni
EP2804845A4 (en) Lithium-ion-conducting materials
EP2920206A4 (en) Modified apol1 polypeptides
GB201203948D0 (en) Detecting polypeptides
HUE047406T2 (en) Polypeptides